Rockefeller Capital Management’s ADC Therapeutics ADCT Stock Holding History

Rockefeller Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.58K	Buy	1,488 +1,057	+245%	+$4.17K	﹤0.01%	4207
2025 Q4	$1.52K	Buy	431 +266	+161%	+$1.08K	﹤0.01%	4378
2025 Q3	$660	Buy	+165	New	+$520	﹤0.01%	4235
2023 Q2	–	Sell	-24,701	Closed	-$48K	–	1807
2023 Q1	$48K	Hold	24,701	–	–	﹤0.01%	1927
2022 Q4	$94K	Sell	24,701 -270	-1%	-$1.08K	﹤0.01%	2055
2022 Q3	$120K	Sell	24,971 -89	-0.4%	-$645	﹤0.01%	1887
2022 Q2	$198K	Buy	25,060 +89	+0.4%	+$842	﹤0.01%	1637
2022 Q1	$365K	Hold	24,971	–	–	﹤0.01%	1444
2021 Q4	$503K	Hold	24,971	–	–	﹤0.01%	1311
2021 Q3	$677K	Hold	24,971	–	–	﹤0.01%	1151
2021 Q2	$607K	Sell	24,971 -54,426	-69%	-$1.26M	﹤0.01%	1112
2021 Q1	$1.94M	Hold	79,397	–	–	0.01%	585
2020 Q4	$2.54M	Buy	+79,397	New	+$2.6M	0.02%	459

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rockefeller Capital Management's ADCT Position: Q1 2026 in Review

Rockefeller Capital Management increased its ADC Therapeutics (ADCT) stake by 245% in Q1 2026, buying an estimated $4.17K and bringing the position to 1,488 shares worth $5.58K. The position accounts for ﹤0.01% of the portfolio, ranked #4207.

Rockefeller Capital Management first reported a position in ADCT in Q4 2020 and has held it in 13 quarters since. The position peaked at $2.54M in Q4 2020. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

Rockefeller Capital Management held 1,488 shares of ADC Therapeutics worth $5.58K as of Q1 2026.
Rockefeller Capital Management bought 1,057 ADC Therapeutics shares in Q1 2026, an estimated $4.17K.
ADC Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4207 holding.
Rockefeller Capital Management first reported a position in ADC Therapeutics in Q4 2020 and has held it in 13 quarters since.
Rockefeller Capital Management's ADC Therapeutics position peaked at $2.54M in Q4 2020.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.